๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Breast Cancer Metastatic
Clinical trial register · China

Breast Cancer Metastatic Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 9 Hangzhou 2 Xi'an 1 Wuhan 1 Kunming 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai9 Hangzhou2 Xi'an1 Wuhan1 Kunming1
All 9 locations
Target enrolment
to

Breast Cancer Metastatic trials in China

18 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Nectin-4 PET to Predict Response to Nectin-4-Targeted Therapy in Advanced Breast Cancer
NCT07708922Breast Cancer Metastatic
Fudan University
Observational
40
Shanghai
2026-06-30
Not yet open
Artificial Intelligence Model-Assisted Accurate Diagnosis of Early-Stage Breast Cancer
NCT07063667Breast Cancer, Metastatic, Artifical Intelligence
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
900
Chongqing
2025-08-01
By invitation
Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
NCT06914661Breast Cancer Metastatic, Efficacy and Safety
The First Hospital of Jilin University
Observational
200
Changchun
2025-05-25
Active, closed
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
NCT06876636Breast Cancer Metastatic
Xijing Hospital
Not applicable
99
Xi'an
2025-03-10
Recruiting
Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
NCT07154563Breast Cancer Metastatic, Sentinel Lymph Node, Sentinel Lymph Node Biopsy (SLNB), Metastasis
Yunnan Cancer Hospital
Observational
60
Kunming
2025-02-01
Recruiting
To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
NCT06784921Breast Cancer Metastatic
Zhejiang Cancer Hospital
Observational
200
Hangzhou
2025-02-01
Recruiting
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
NCT06718933Breast Cancer Metastatic, Breast Cancer Brain Metastases
Fudan University
Phase 1/2
74
Shanghai
2025-01-08
Active, closed
A ReaL World Study of DS-8201
NCT06945224Breast Cancer Metastatic, Treatment Efficacy
Fudan University
Observational
300
Shanghai
2024-12-01
Recruiting
21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis
NCT06891651Breast Cancer Metastatic, Breast Cancer Survival
Qilu Hospital of Shandong University
Observational
35
Jinan
2024-12-01
Recruiting
HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity
NCT07586215Breast Cancer Metastatic
Fudan University
Observational
100
Shanghai
2024-11-11
Recruiting
Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
NCT06658080Breast Cancer Metastatic, Hydrothorax, Ascites, Organoids
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
90
Hangzhou
2024-11-09
Recruiting
Target-specific immunoPET Imaging of Breast Cancer
NCT06715826Breast Cancer, Breast Neoplasms, Breast Cancer Metastatic
RenJi Hospital
Phase 1/2
200
Shanghai
2024-09-21
Active, closed
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT06612814Breast Cancer Metastatic
Zhimin Shao
Phase 3
307
Shanghai
2024-09-01
Recruiting
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
NCT06532812Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic, Breast Cancer Triple Negative
Essen Biotech
Phase 1/2
85
Beijing
2024-08-22
Recruiting
A Real World Study of Sacituzumab Govitecan
NCT06966141Breast Cancer Metastatic, Treatment Outcome
Fudan University
Observational
100
Shanghai
2024-08-12
Active, closed
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
NCT05759572Breast Cancer Metastatic
Fudan University
Phase 2
145
Shanghai
2023-03-01
Recruiting
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT05759546Breast Cancer Metastatic
Fudan University
Phase 2
200
Shanghai
2023-02-01
Recruiting
Integrin ฮฑvฮฒ6-targeted PET in Malignant Tumors
NCT05835570Malignant Neoplasm, PET/CT, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic
Zhongnan Hospital
Observational
200
Wuhan
2023-01-01
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/breast-cancer-metastatic

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies listing the condition Breast Cancer Metastatic.

How many Breast Cancer Metastatic trials are recruiting in China?

11 of the 18 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 5 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Breast Cancer Metastatic), 18 studies
PhaseStudiesRecruitingShare
Observational11761.1%
Phase 1/23316.7%
Phase 22111.1%
Not applicable105.6%
Phase 3105.6%

Most active sponsors

Lead sponsors with the most studies (Breast Cancer Metastatic)
Lead sponsorStudiesRecruiting
Fudan University74
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University10
Essen Biotech11
Qilu Hospital of Shandong University11
RenJi Hospital11
Second Affiliated Hospital, Zhejiang University, School of Medicine11
The First Hospital of Jilin University10
Xijing Hospital10
Yunnan Cancer Hospital11
Zhejiang Cancer Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.